Entropy Neurodynamics has been granted an Australian patent for its novel two-phase IV infusion method administering psilocybin and psilocin, securing exclusive rights through 2042 and strengthening its lead asset TRP-8803’s competitive position.
- Australian patent granted for precision-controlled two-phase IV dosing method
- Protection extends to psilocybin, psilocin, and related compounds through 2042
- Patent covers rapid onset, controlled maintenance, treatment stoppage, and EEG monitoring
- Broad application across neuropsychiatric and nociplastic pain disorders
- Creates a strong competitive moat and supports multi-indication platform development
Patent Grant Strengthens TRP-8803’s IP Position
Entropy Neurodynamics Limited (ASX – ENP), a clinical-stage biotech company focused on neuropsychiatric therapeutics, has secured a significant Australian patent that protects its innovative method for administering psychedelic compounds intravenously. This patent covers a precision-controlled, two-phase dosing regimen for psilocybin, psilocin, and related chemical variants, underpinning the company’s lead asset, TRP-8803.
The granted patent extends Entropy’s intellectual property protection through to 2042, providing a long-term competitive advantage. It safeguards a unique intravenous (IV) infusion method that begins with a rapid loading dose to induce the therapeutic psychedelic state within 5 to 30 minutes, followed by a controlled maintenance infusion to sustain consistent drug levels. This approach contrasts sharply with traditional oral dosing, which is slower and less predictable.
Clinical and Commercial Advantages of the Two-Phase IV Model
One of the key differentiators of Entropy’s method is the ability to stop treatment instantly by halting the infusion, offering clinicians precise control over the psychedelic experience. This feature enhances safety and operational flexibility, which are difficult to achieve with oral administration. Additionally, the patent protects the use of EEG-based monitoring to track brain activity in real time, supporting the development of objective biomarkers that could optimise dosing and improve clinical outcomes.
By securing method-level protection rather than just molecule-based patents, Entropy has created a formidable barrier to entry. Competitors aiming to replicate a similar controlled IV psychedelic therapy would likely infringe on this patent, limiting direct competition in this space.
Broad Therapeutic Scope and Future-Proofing
The patent’s claims cover a wide range of neuropsychiatric and nociplastic pain conditions, including anxiety, PTSD, addiction, eating disorders, fibromyalgia, and other chronic pain syndromes. Moreover, the protection extends across multiple delivery routes beyond IV, such as oral, transdermal, subcutaneous, and intranasal, positioning Entropy to adapt as new drug delivery technologies emerge.
Entropy’s CEO, Jason Carroll, emphasised the strategic importance of this patent, highlighting its role in securing exclusivity around how psychedelic therapies are delivered, monitored, and controlled. This comprehensive protection supports the company’s vision of developing a scalable, multi-indication platform and enhances its appeal to potential strategic partners focused on next-generation neuropsychiatric treatments.
Looking Ahead
While this announcement pertains to the Australian patent, Entropy has corresponding applications underway in other key jurisdictions, including the United States. The outcomes of these applications will be closely watched by investors and industry observers, as they will further define the company’s global IP landscape.
As TRP-8803 progresses through clinical development, this patent grant not only solidifies Entropy’s technological edge but also lays the groundwork for future regulatory and reimbursement strategies, particularly through its integration of EEG biomarker monitoring.
Bottom Line?
This patent grant cements Entropy’s lead in precision-controlled psychedelic therapy, setting the stage for clinical and commercial milestones ahead.
Questions in the middle?
- How will Entropy’s international patent applications progress and impact global market exclusivity?
- What clinical trial results will confirm the safety and efficacy advantages of the two-phase IV dosing model?
- How might competitors respond to this method-level patent barrier in the evolving psychedelic therapy landscape?